Operaciones Neoleukin Therapeutics, Inc. - NLTX CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Condiciones de trading
| Diferencial | - | ||||||||
|
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.025457% | ||||||||
|
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | 0.003235% | ||||||||
| Horario tarifa nocturna | 21:00 (UTC) | ||||||||
| Cantidad comercializada mínima | 1 | ||||||||
| Divisa | USD | ||||||||
| Margen | 20% | ||||||||
| Mercado de valores | United States of America | ||||||||
| Comisión por operación | 0% |
*Information provided by Capital.com
Neoleukin Therapeutics Inc ESG Risk Ratings
High Medium Low Negligible
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Estadísticas clave
| Cierre previo* | N/A |
| Abrir* | N/A |
| Cambio de 1 año* | N/A |
| Rango del día* | N/A |
| Rango de 52 semanas | 0.38-1.34 |
| Volumen medio (10 días) | 98.09K |
| Volumen medio (3 meses) | 9.10M |
| Capitalización de mercado | 35.12M |
| Ratio P/E | -100.00K |
| Acciones en circulación | 42.83M |
| Ingresos | N/A |
| EPS | -1.02 |
| Dividendo (Rendimiento %) | N/A |
| Beta | 1.25 |
| Próxima fecha de resultados | Aug 7, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Cierre | Change | Change (%) | Apertura | High | Low |
|---|
Neoleukin Therapeutics, Inc. Events
| Hora (UTC) (UTC) | País | Evento |
|---|---|---|
| Thursday, June 8, 2023 | ||
| Hora (UTC) (UTC) 20:30 | País CA
| Evento Neoleukin Therapeutics Inc Annual Shareholders Meeting Neoleukin Therapeutics Inc Annual Shareholders MeetingForecast -Previous - |
| Monday, August 7, 2023 | ||
| Hora (UTC) (UTC) 10:59 | País CA
| Evento Q2 2023 Neoleukin Therapeutics Inc Earnings Release Q2 2023 Neoleukin Therapeutics Inc Earnings ReleaseForecast -Previous - |
| Monday, November 13, 2023 | ||
| Hora (UTC) (UTC) 10:59 | País CA
| Evento Q3 2023 Neoleukin Therapeutics Inc Earnings Release Q3 2023 Neoleukin Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Ingresos totales | 0 | 0 | 0 | 0 | 25 |
| Gastos totales de explotación | 59.097 | 60.698 | 33.728 | 70.959 | 57.624 |
| Gastos de venta/general/administración Gastos, total | 17.968 | 21.536 | 17.21 | 18.126 | 15.835 |
| Investigación y desarrollo | 41.129 | 39.162 | 24.344 | 6.317 | 41.789 |
| Ingresos de explotación | -59.097 | -60.698 | -33.728 | -70.959 | -32.624 |
| Ingresos por intereses (gastos), netos No operativos | 1.582 | 0.018 | 0.495 | 1.525 | 1.484 |
| Otros, netos | -0.042 | -0.012 | -0.044 | -0.008 | -0.445 |
| Ingresos netos antes de impuestos | -57.557 | -60.692 | -33.277 | -69.442 | -31.585 |
| Ingresos netos después de impuestos | -57.557 | -60.692 | -33.277 | -69.442 | -31.585 |
| Beneficio neto antes de partidas extra. Elementos | -57.557 | -60.692 | -33.277 | -69.442 | -31.585 |
| Ingresos netos | -57.557 | -60.692 | -33.277 | -69.442 | -31.585 |
| Total Adjustments to Net Income | |||||
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -57.557 | -60.692 | -33.277 | -69.442 | -31.585 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -57.557 | -60.692 | -33.277 | -69.442 | -31.585 |
| Ajuste por dilución | |||||
| Beneficio neto diluido | -57.557 | -60.692 | -33.277 | -69.442 | -31.585 |
| Promedio ponderado de acciones diluidas | 55.2212 | 55.0417 | 51.825 | 27.0304 | 23.5195 |
| BPA diluido sin partidas extraordinarias | -1.0423 | -1.10266 | -0.6421 | -2.56904 | -1.34293 |
| BPA normalizado diluido | -1.0423 | -1.10266 | -0.79311 | -0.84816 | -1.34293 |
| Total de partidas extraordinarias | |||||
| Ingresos | 0 | 25 | |||
| Gastos (ingresos) extraordinarios | 0 | -7.826 | 46.516 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Ingresos totales | 0 | 0 | 0 | 0 | 0 |
| Gastos totales de explotación | 15.135 | 14.251 | 13.609 | 15.871 | 15.365 |
| Gastos de venta/general/administración Gastos, total | 4.027 | 4.25 | 4.138 | 4.915 | 4.664 |
| Investigación y desarrollo | 7.69 | 10.001 | 9.471 | 10.956 | 10.701 |
| Ingresos de explotación | -15.135 | -14.251 | -13.609 | -15.871 | -15.365 |
| Ingresos por intereses (gastos), netos No operativos | 0.945 | 0.808 | 0.56 | 0.199 | 0.014 |
| Otros, netos | -0.014 | -0.002 | -0.023 | -0.016 | 0 |
| Ingresos netos antes de impuestos | -14.204 | -13.445 | -13.072 | -15.688 | -15.351 |
| Ingresos netos después de impuestos | -14.204 | -13.445 | -13.072 | -15.688 | -15.351 |
| Beneficio neto antes de partidas extra. Elementos | -14.204 | -13.445 | -13.072 | -15.688 | -15.351 |
| Ingresos netos | -14.204 | -13.445 | -13.072 | -15.688 | -15.351 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -14.204 | -13.445 | -13.072 | -15.688 | -15.351 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -14.204 | -13.445 | -13.072 | -15.688 | -15.351 |
| Beneficio neto diluido | -14.204 | -13.445 | -13.072 | -15.688 | -15.351 |
| Promedio ponderado de acciones diluidas | 55.4209 | 55.2852 | 55.251 | 55.2037 | 55.1435 |
| BPA diluido sin partidas extraordinarias | -0.25629 | -0.24319 | -0.23659 | -0.28418 | -0.27838 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| BPA normalizado diluido | -0.19462 | -0.24319 | -0.23659 | -0.28418 | -0.27838 |
| Gastos (ingresos) extraordinarios | 3.418 |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 99.134 | 143.989 | 194.522 | 143.596 | 77.165 |
| Efectivo e inversiones a corto plazo | 96.384 | 142.467 | 192.556 | 143.093 | 76.928 |
| Cash | 25.061 | ||||
| Efectivo y Equivalentes | 37.887 | 142.467 | 192.556 | 143.093 | 51.867 |
| Inversiones a corto plazo | 58.497 | 0 | |||
| Total deudores, neto | 0.9 | 0.503 | 0.237 | ||
| Accounts Receivable - Trade, Net | 0.9 | 0.503 | 0.237 | ||
| Total Assets | 115.948 | 163.263 | 210.519 | 147.023 | 77.618 |
| Property/Plant/Equipment, Total - Net | 15.878 | 17.218 | 13.724 | 2.83 | 0.4 |
| Property/Plant/Equipment, Total - Gross | 18.83 | 18.853 | 14.309 | 3.518 | 0.843 |
| Accumulated Depreciation, Total | -2.952 | -1.635 | -0.585 | -0.688 | -0.443 |
| Long Term Investments | |||||
| Total Current Liabilities | 11.062 | 8.636 | 7.889 | 4.743 | 4.627 |
| Accounts Payable | 0.478 | 0.526 | 1.323 | 1.604 | 0.702 |
| Accrued Expenses | 10.444 | 8.055 | 6.517 | 3.077 | 3.925 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 21.617 | 20.399 | 19.303 | 5.336 | 4.946 |
| Total Long Term Debt | 0.233 | 0.067 | 0.108 | 0.146 | 0.006 |
| Capital Lease Obligations | 0.233 | 0.067 | 0.108 | 0.146 | 0.006 |
| Other Liabilities, Total | 10.322 | 11.696 | 11.306 | 0.447 | 0.313 |
| Total Equity | 94.331 | 142.864 | 191.216 | 141.687 | 72.672 |
| Redeemable Preferred Stock | |||||
| Common Stock | 0.00004 | 0.00004 | 0.00004 | 0.00004 | 0 |
| Additional Paid-In Capital | 545.407 | 536.362 | 524.022 | 441.216 | 302.759 |
| Retained Earnings (Accumulated Deficit) | -451.055 | -393.498 | -332.806 | -299.529 | -230.087 |
| Other Equity, Total | -0.02104 | -0.00004 | -0.00004 | -0.00004 | 0 |
| Total Liabilities & Shareholders’ Equity | 115.948 | 163.263 | 210.519 | 147.023 | 77.618 |
| Total Common Shares Outstanding | 42.6483 | 42.4575 | 42.1963 | 37.9968 | 23.5374 |
| Other Long Term Assets, Total | 0.936 | 1.928 | 1.926 | 0.03 | 0.053 |
| Intangibles, Net | 0 | 0.128 | 0.347 | 0.567 | |
| Current Port. of LT Debt/Capital Leases | 0.14 | 0.055 | 0.049 | 0.062 | |
| Other Current Assets, Total | 2.75 | 1.522 | 1.066 | ||
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 85.636 | 99.134 | 108.857 | 118.485 | 130.365 |
| Efectivo e inversiones a corto plazo | 83.436 | 96.384 | 106.878 | 116.457 | 128.057 |
| Efectivo y Equivalentes | 35.494 | 37.887 | 40.335 | 77.526 | 128.057 |
| Other Current Assets, Total | 2.2 | 2.75 | 1.979 | 2.028 | 2.308 |
| Total Assets | 98.46 | 115.948 | 126.576 | 137.021 | 149.126 |
| Property/Plant/Equipment, Total - Net | 11.919 | 15.878 | 15.807 | 16.498 | 16.743 |
| Intangibles, Net | 0 | 0 | 0.018 | 0.073 | |
| Other Long Term Assets, Total | 0.905 | 0.936 | 1.912 | 2.02 | 1.945 |
| Total Current Liabilities | 7.156 | 11.062 | 10.237 | 9.271 | 7.596 |
| Payable/Accrued | 5.421 | 9.547 | 8.858 | 7.886 | 6.325 |
| Accrued Expenses | 1.431 | 1.375 | 1.32 | 1.267 | 1.216 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.304 | 0.14 | 0.059 | 0.118 | 0.055 |
| Total Liabilities | 17.103 | 21.617 | 20.929 | 20.313 | 19.033 |
| Total Long Term Debt | 0.007 | 0.233 | 0.009 | 0.01 | 0.066 |
| Capital Lease Obligations | 0.007 | 0.233 | 0.009 | 0.01 | 0.066 |
| Other Liabilities, Total | 9.94 | 10.322 | 10.683 | 11.032 | 11.371 |
| Total Equity | 81.357 | 94.331 | 105.647 | 116.708 | 130.093 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.00004 | 0.00004 | 0.00004 | 0.00004 | 0.00004 |
| Additional Paid-In Capital | 546.598 | 545.407 | 543.348 | 541.317 | 538.942 |
| Retained Earnings (Accumulated Deficit) | -465.259 | -451.055 | -437.609 | -424.537 | -408.849 |
| Other Equity, Total | 0.01796 | -0.02104 | -0.09204 | -0.07204 | -0.00004 |
| Total Liabilities & Shareholders’ Equity | 98.46 | 115.948 | 126.576 | 137.021 | 149.126 |
| Total Common Shares Outstanding | 42.8184 | 42.6483 | 42.5946 | 42.5798 | 42.494 |
| Property/Plant/Equipment, Total - Gross | 12.057 | ||||
| Accumulated Depreciation, Total | -1.026 | ||||
| Inversiones a corto plazo | 47.942 | 58.497 | 66.543 | 38.931 |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Ingresos netos/Línea de salida | -57.557 | -60.692 | -33.277 | -69.442 | -31.585 |
| Efectivo de actividades de explotación | -45.607 | -47.558 | -24.575 | -15.394 | -31.577 |
| Partidas no monetarias | 9.504 | 12.528 | 6.951 | 55.662 | 5.439 |
| Intereses pagados en efectivo | 0.001 | 0.004 | |||
| Cambios en el capital circulante | 0.885 | -0.7 | 0.966 | -1.954 | -5.431 |
| Efectivo de actividades de inversión | -59.134 | -3.263 | -2.219 | -0.688 | 55.951 |
| Gastos de capital | -1.11 | -3.263 | -2.219 | -0.879 | -0.049 |
| Otras partidas de flujo de caja de inversión, total | -58.024 | 0 | 0.191 | 56 | |
| Efectivo procedente de actividades de financiación | 0.161 | 0.732 | 77.135 | 82.237 | 0.57 |
| Elementos de flujo de caja de financiación | 0 | -0.355 | -5.525 | 0 | |
| Emisión (retiro) de acciones, neto | 0.216 | 0.783 | 77.539 | 87.771 | 0.602 |
| Emisión (amortización) de deuda, neta | -0.055 | -0.051 | -0.049 | -0.009 | -0.032 |
| Efectos del cambio de divisas | 0 | 0.01 | -0.048 | ||
| Variación neta de la tesorería | -104.58 | -50.089 | 50.341 | 66.165 | 24.896 |
| Efectivo de actividades de explotación | 1.561 | 1.306 | 0.785 | 0.34 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -14.204 | -57.557 | -44.112 | -31.039 | -15.351 |
| Cash From Operating Activities | -13.033 | -45.607 | -34.674 | -25.385 | -14.091 |
| Cash From Operating Activities | 0.329 | 1.561 | 1.193 | 0.87 | 0.411 |
| Non-Cash Items | 4.554 | 9.504 | 7.568 | 5.27 | 2.696 |
| Changes in Working Capital | -3.712 | 0.885 | 0.677 | -0.486 | -1.847 |
| Cash From Investing Activities | 10.706 | -59.134 | -67.601 | -39.751 | -0.452 |
| Capital Expenditures | -0.419 | -1.11 | -1.006 | -0.684 | -0.452 |
| Cash From Financing Activities | -0.066 | 0.161 | 0.143 | 0.195 | 0.133 |
| Issuance (Retirement) of Stock, Net | 0 | 0.216 | 0.197 | 0.197 | 0.134 |
| Issuance (Retirement) of Debt, Net | -0.066 | -0.055 | -0.054 | -0.002 | -0.001 |
| Foreign Exchange Effects | |||||
| Net Change in Cash | -2.393 | -104.58 | -102.132 | -64.941 | -14.41 |
| Financing Cash Flow Items | |||||
| Other Investing Cash Flow Items, Total | 11.125 | -58.024 | -66.595 | -39.067 |
| Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
|---|---|---|---|---|---|---|
| Baker Bros. Advisors LP | Hedge Fund | 8.9234 | 3821740 | 0 | 2023-03-31 | LOW |
| Ulge (Umut) | Individual Investor | 6.4891 | 2779191 | 0 | 2023-04-20 | |
| Silva Manzano (Daniel Adriano) | Individual Investor | 5.9735 | 2558335 | 0 | 2023-04-20 | |
| Lynx1 Capital Advisors LLC | Investment Advisor | 5.6699 | 2428323 | 137190 | 2023-03-31 | |
| Drachman (Jonathan) | Individual Investor | 5.6007 | 2398686 | 0 | 2023-04-20 | |
| Redmile Group, LLC | Investment Advisor/Hedge Fund | 4.314 | 1847600 | -2966 | 2023-03-31 | LOW |
| BofA Global Research (US) | Research Firm | 2.7011 | 1156845 | -467048 | 2023-03-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.373 | 1016296 | 0 | 2023-03-31 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 2.1355 | 914613 | -278834 | 2023-03-31 | HIGH |
| Millennium Management LLC | Hedge Fund | 1.8146 | 777148 | -810119 | 2023-03-31 | HIGH |
| Morgan Stanley & Co. LLC | Research Firm | 1.4025 | 600656 | 271140 | 2023-03-31 | MED |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.2618 | 540425 | -49467 | 2023-03-31 | LOW |
| Two Sigma Investments, LP | Hedge Fund | 1.1158 | 477885 | -71451 | 2023-03-31 | HIGH |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7029 | 301057 | 0 | 2023-03-31 | LOW |
| Morgan Stanley Smith Barney LLC | Investment Advisor | 0.516 | 221009 | -11189 | 2023-03-31 | LOW |
| ACT Capital Management, L.L.C. | Hedge Fund | 0.4646 | 199000 | 0 | 2022-09-30 | MED |
| Point72 Asset Management, L.P. | Hedge Fund | 0.3191 | 136675 | 0 | 2023-03-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.2862 | 122556 | 0 | 2023-03-31 | LOW |
| Kynam Capital Management LP | Hedge Fund | 0.2801 | 119966 | -798 | 2023-03-31 | MED |
| Privium Fund Management (UK) Ltd | Investment Advisor | 0.2737 | 117200 | 0 | 2023-03-31 | HIGH |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group530K+
Traders
87K+
Clientes activos mensualmente
$46M+
Volumen mensual de inversión
$31M+
Retiros por mes
Calculadora de trading
Calcula tus P&L hipotéticas en el supuesto de haber abierto una operación con CFD en una fecha determinada (selecciona una fecha) y haberla cerrado en otra fecha (selecciona una fecha).
Comisión de la operación
0
- 1:1
Apalancamiento
1:1
- 20
- 100
- 500
- 1000
- 10000
Inversión
Tamaño de la operación (Apalancamiento x Inversión)
Apertura
Cierre
En corto En largo
Neoleukin Therapeutics, Inc. Company profile
Sobre Neoleukin Therapeutics Inc
Neoleukin Therapeutics, Inc. es una empresa biofarmacéutica. La empresa se dedica a proporcionar inmunoterapias para el cáncer, la inflamación y la autoinmunidad utilizando la tecnología de diseño de proteínas de novo. La empresa utiliza métodos computacionales para diseñar proteínas que demuestren propiedades farmacéuticas específicas. Sus principales áreas de interés son la oncología, la inflamación y la autoinmunidad. Su tecnología, la plataforma Neoleukin, utiliza un conjunto de algoritmos y métodos computacionales avanzados para diseñar proteínas funcionales de novo. El programa principal de Neoleukin, NL-201, es una proteína terapéutica de novo diseñada computacionalmente. El NL-201 está diseñado para ser utilizado como agente único o en combinación con modalidades terapéuticas complementarias. El NL-201 también ha demostrado ser prometedor en combinación con la terapia celular alogénica para ampliar y mantener las poblaciones de células CAR-T y NK trasplantadas.
El precio actual de la acción Neoleukin Therapeutics, Inc. en tiempo real es 0 USD. El gráfico de la acción permite a los inversores comprender mejor el rendimiento y el precio de la acción y tomar decisiones informadas al negociar acciones y CFD.
Descubra más acciones con gráficos, datos vitales y actualizaciones de precios en tiempo real: Viatris Inc., ZIPRECRUITER, Wharf (Holdings) Limited, First Resources, EastGroup Properties, Inc. y SAB Biotherapeutics, Inc.. Para obtener más información, consulte los perfiles de las empresas en Capital.com.
| Industry: | Biotechnology & Medical Research (NEC) |
1616 Eastlake Ave E Ste 360
SEATTLE
WASHINGTON 98102-3795
US
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 530.000 traders de todo el mundo que eligen operar con Capital.com